Treating Advanced RAI-Refractory DTC: A Two-Way Street: Medical Oncology and Endocrinology

home / insights / treating-advanced-rai-refractory-dtc-a-two-way-street

Differentiated Thyroid Cancer: Increasing Incidence

EP. 1: Differentiated Thyroid Cancer: Increasing Incidence

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
December 14th 2020
DTC: Histological Subtypes and Tumor Differentiation

EP. 2: DTC: Histological Subtypes and Tumor Differentiation

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
December 14th 2020
Role of Radioiodine Treatment in DTC

EP. 3: Role of Radioiodine Treatment in DTC

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
December 21st 2020
Thyrotropin Suppression as DTC Treatment Option

EP. 4: Thyrotropin Suppression as DTC Treatment Option

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
December 21st 2020
Clinical Scenarios to Consider for RAI-Refractory DTC

EP. 5: Clinical Scenarios to Consider for RAI-Refractory DTC

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
January 4th 2021
Discussing Iodine-Refractory DTC With Patients

EP. 6: Discussing Iodine-Refractory DTC With Patients

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
January 4th 2021
Management of DTC in Clinical Practice

EP. 7: Management of DTC in Clinical Practice

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
January 11th 2021
Roles and Communication in Treatment in DTC

EP. 8: Roles and Communication in Treatment in DTC

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
January 11th 2021
Understanding Sequencing and What to Look for in DTC

EP. 9: Understanding Sequencing and What to Look for in DTC

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
January 18th 2021
Approaching Treatment of Low-Volume DTC

EP. 10: Approaching Treatment of Low-Volume DTC

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
January 18th 2021
Multidisciplinary Management for the Treatment of DTC

EP. 11: Multidisciplinary Management for the Treatment of DTC

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
January 18th 2021
RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT

EP. 12: RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
January 21st 2021
Sorafenib and Lenvatinib Side Effect Profile and Dosing

EP. 13: Sorafenib and Lenvatinib Side Effect Profile and Dosing

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
January 21st 2021
Molecular Testing in Treatment Selection

EP. 14: Molecular Testing in Treatment Selection

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
January 28th 2021
Advice for Managing RAI-Refractory DTC

EP. 15: Advice for Managing RAI-Refractory DTC

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
January 28th 2021
LIBRETTO-001 Phase 1/2 Trial Overview

EP. 16: LIBRETTO-001 Phase 1/2 Trial Overview

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
February 4th 2021
Rationale for Sequencing in Second Line

EP. 17: Rationale for Sequencing in Second Line

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
February 4th 2021
The Future of RAI-Refractory DTC Management

EP. 18: The Future of RAI-Refractory DTC Management

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
February 11th 2021
Treating BRAF V600 and NTRK Gene Fusion Positivity

EP. 19: Treating BRAF V600 and NTRK Gene Fusion Positivity

Lori J. Wirth, MD, Massachusetts General Hospital;Jennifer Sipos, MD, Ohio State University;Frank Worden, MD
February 11th 2021